Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

chemi s.p.a. - octreotide - octreotide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

novartis farma s.p.a. - octreotide - octreotide

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novo nordisk pharma ag - insulinum detemirum - soluzione iniettabile - insulinum detemirum 100 u., natrii chloridum, zincum, glycerolum, natrii phosphates, conserv.: metacresolum 2.06 mg, phenolum 1.8 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - il diabete mellito - biotechnologika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - octreotide - octreotide

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

boehringer ingelheim (schweiz) gmbh - linagliptinum - compresse rivestite con film - linagliptinum 5 mg, mannitolum, amylum pregelificatum, maydis amylum, copovidonum, magnesii stearas, Überzug: hypromellosum, e 171, talcum, macrogolum 6000, e 172 (rubrum), pro compresso obducto. - antidiabetico - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

intas third party sales 2005, s.l. - vildagliptin - vildagliptin

Unione Europea - italiano - EMA (European Medicines Agency)

sanofi winthrop industrie - l'insulina glargine, lixisenatide - diabete mellito, tipo 2 - farmaci usati nel diabete - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novo nordisk pharma ag - insulinum detemirum - soluzione iniettabile - insulinum detemirum 100 u., natrii chloridum, zincum, glycerolum, natrii phosphates, conserv.: metacresolum 2.06 mg, phenolum 1.8 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - il diabete mellito - biotechnologika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - linagliptin - linagliptin